https://www.selleckchem.com/products/ABT-888.html
Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly. There is limited data assessing the efficacy and tolerability of abiraterone acetate (AA) versus enzalutamide in this population. To compare the clinical efficacy and tolerability of AA versus enzalutamide in patients≥80 years with mCRPC. A retrospective propensity-weighted comparative cohort study of first-line AA versus enzalutamide amongpatients with mCRPC aged ≥80 years. Inverse probability treatment weights based on propensity scores wer
Aimer
Commentaire
Partagez
